<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>532</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15603888</PubmedId>
            <Abstract>Prognosis of disseminated melanoma remains gloomy as neither chemotherapeutic nor unspecific immune modulatory approaches were able to improve the overall survival of these patients. Hence, specific immunotherapy has received increasing attention. Disappointing clinical results, however, indicate that the choice of suitable antigens is of special importance. To this end, the inhibitor of apoptosis (IAP) protein survivin, which is over-expressed in several tumours but is largely undetectable in adult tissues, appears to be a promising target for vaccination purposes, since down-regulation or loss of expression is associated with impaired tumour progression. Consequently, five heavily pretreated stage IV melanoma patients were vaccinated with the HLA-A2 restricted survivin(96-104) epitope presented by autologous dendritic cells (DCs) in a compassionate use setting. Four of these patients mounted strong T cell responses to this epitope as measured by ELISPOT assay. Furthermore, in situ peptide/HLA-A2 multimer staining confirmed that these survivin reactive cells infiltrated both visceral and soft tissue metastases.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>884-9</ArticlePages>
            <ArticleTitle>Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Otto</LastName>
                    <ForeName>Kerstin</ForeName>
                </Author>
                <Author>
                    <LastName>Andersen</LastName>
                    <ForeName>Mads Hald</ForeName>
                </Author>
                <Author>
                    <LastName>Eggert</LastName>
                    <ForeName>Andreas</ForeName>
                </Author>
                <Author>
                    <LastName>Keikavoussi</LastName>
                    <ForeName>Petra</ForeName>
                </Author>
                <Author>
                    <LastName>Pedersen</LastName>
                    <ForeName>Lars Østergaard</ForeName>
                </Author>
                <Author>
                    <LastName>Rath</LastName>
                    <ForeName>Jörg C</ForeName>
                </Author>
                <Author>
                    <LastName>Böck</LastName>
                    <ForeName>Markus</ForeName>
                </Author>
                <Author>
                    <LastName>Bröcker</LastName>
                    <ForeName>Eva-B</ForeName>
                </Author>
                <Author>
                    <LastName>Straten</LastName>
                    <ForeName>Per Thor</ForeName>
                </Author>
                <Author>
                    <LastName>Kämpgen</LastName>
                    <ForeName>Eckhart</ForeName>
                </Author>
                <Author>
                    <LastName>Becker</LastName>
                    <ForeName>Jürgen C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Dermatology and Venerology, University of Würzburg, Josef-Schneider-Strasse 2, Building 13, 97080 Würzburg, Germany.</Affiliations>
            <ArticleChemicalList>Antigens, Neoplasm;BIRC5 protein, human;Cancer Vaccines;HLA-A2 Antigen;Inhibitor of Apoptosis Proteins;Microtubule-Associated Proteins;Neoplasm Proteins;Survivin</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adult; Aged; Antigens, Neoplasm(adverse effects; immunology; therapeutic use); Cancer Vaccines(adverse effects; immunology; therapeutic use); Female; HLA-A2 Antigen(immunology); Humans; Inhibitor of Apoptosis Proteins; Male; Melanoma(immunology; therapy); Microtubule-Associated Proteins(adverse effects; immunology; therapeutic use); Middle Aged; Neoplasm Proteins; Survivin; T-Lymphocytes(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>23</Volume>
                <Issue>7</Issue>
                <Title>Vaccine</Title>
                <Issn>1873-2518</Issn>
                <MedlineTa>Vaccine</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Survivin &lt;sub&gt;96-104&lt;/sub&gt;</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>LMLGEFLKL</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <EpitopeRelatedObject>
                    <RelatedObjectType>The epitope is an analog of:</RelatedObjectType>
                    <RelatedObject>
                        <FragmentOfANaturalSequenceMolecule>
                            <ChemicalType>Peptide from protein</ChemicalType>
                            <LinearSequence>LTLGEFLKL</LinearSequence>
                            <StartingPosition>96</StartingPosition>
                            <EndingPosition>104</EndingPosition>
                            <SourceMolecule>
                                <GenBankId>O15392.3</GenBankId>
                            </SourceMolecule>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </FragmentOfANaturalSequenceMolecule>
                    </RelatedObject>
                </EpitopeRelatedObject>
                <LocationOfData>Page 885</LocationOfData>
                <EpitopeId>38060</EpitopeId>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>The epitope used was a modified version of the natural epitope.  It was modified by replacing threonine at position 2 with methionine,a better anchor residue with improved binding affinityto the MHC molecule.</EpitopeComments>
                <Assays>
                    <TCell>
                        <TCellId>8557</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>40-73 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>LMLGEFLKL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Survivin &lt;sub&gt;96-104&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intradermal</Route>
                                <DoseSchedule>Patients were vaccinated at 7-day intervals for the first two vaccinations followed by 28-day intervals for further vaccinations.  Total number of vaccinations ranged from 2 to 15.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>LMLGEFLKL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Stage IV cutaneous or uveal melanoma HLA-A*0201+ patients, whose disease was progressive despite at least two different chemo-, immuno- or chemoimmunotherapies were studied.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Survivin &lt;sub&gt;96-104&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>LMLGEFLKL</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>80</ResponseFrequency>
                            <AssayComments>The presence of survivin96–104/HLA-A*0201 reactive CD8+ T lymphocytes among tumor infiltrating lymphocytes was measured in situ by peptide/MHC multimer staining.  This analysis confirmed that intradermal injections of peptide-pulsed DC induce a strong peptide-specific inflammatory T cell infiltrate. The peptide/MHC multimer staining procedure was also applied to soft tissue and visceral metastases, revealing the presence of survivin96–104/HLA-A*0201 reactive cells among the CD8+ infiltrate.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>4066</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <Age>40-73 years old</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Chronic</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>LMLGEFLKL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Survivin &lt;sub&gt;96-104&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intradermal</Route>
                                <DoseSchedule>Patients were vaccinated at 7-day intervals for the first two vaccinations followed by 28-day intervals for further vaccinations.  Total number of vaccinations ranged from 2 to 15.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>LMLGEFLKL</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Stage IV cutaneous or uveal melanoma HLA-A*0201+ patients, whose disease was progressive despite at least two different chemo-, immuno- or chemoimmunotherapies were studied.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Survivin &lt;sub&gt;96-104&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>LMLGEFLKL</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>5</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>80</ResponseFrequency>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

